JCR Pharmaceuticals has developed a bifunctional fusion antibody designed to treat iduronate 2-sulfatase deficiency in the central nervous system. This antibody crosses the blood-brain barrier and retains significant enzymatic activity, facilitating the hydrolysis of specific sulfate groups in glycosaminoglycans. GlobalData’s report on JCR Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on JCR Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. JCR Pharmaceuticals's grant share as of June 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Fusion antibody for treating iduronate 2-sulfatase deficiency
The granted patent US12043661B2 describes a novel fusion antibody designed to cross the blood-brain barrier (BBB) and deliver therapeutic effects for conditions associated with glycosaminoglycan (GAG) accumulation. The fusion antibody comprises an immunoglobulin heavy chain or a fragment thereof, covalently linked to an iduronate-2-sulfatase with a specific amino acid sequence (SEQ ID NO: 9). This unique structure allows the fusion protein to utilize the transferrin receptor for BBB penetration while maintaining at least 20% of the iduronate-2-sulfatase's enzymatic activity compared to its standalone form. The fusion antibody is also capable of catalyzing the hydrolysis of 2-sulfate groups from L-iduronate 2-sulfate units found in dermatan sulfate, heparan sulfate, or heparin.
Further claims within the patent detail additional features of the fusion antibody, including the potential incorporation of an immunoglobulin light chain, which may be of either lambda or kappa class. The fusion antibody can undergo post-translational modifications by a sulfatase modifying factor type 1 (SUMF1) and is characterized by a specific activity of at least 10,000 units/mg for the iduronate-2-sulfatase. Notably, the fusion antibody has demonstrated efficacy in reducing GAG accumulation in Hunter fibroblasts, indicating its therapeutic potential in treating related lysosomal storage disorders. The claims emphasize the retention of functional activity for both the iduronate-2-sulfatase and the immunoglobulin components, ensuring the effectiveness of the fusion antibody in a central nervous system environment.
To know more about GlobalData’s detailed insights on JCR Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
